Portola Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic conditions. The Company's first two commercialized products are AndexxaÂŽ [coagulation factor Xa (recombinant), inactivated-zhzo], marketed in Europe as OndexxyaÂŽ (andexanet alfa), and BevyxxaÂŽ (betrixaban). The company also is advancing cerdulatinib, an investigational SYK/JAK inhibitor being developed for the treatment of hematologic cancers. Founded in 2003 in South San Francisco, California, Portola has operations in the United States and Europe. Source
No articles found.
RB is the global leading consumer health, hygiene and home company. Driven by a pu...
RB is the global leading consumer health, hygie...
Bio-Path is a biotechnology company developing targeted therapies for acute myeloi...
Bio-Path is a biotechnology company developing ...
OptimizeRxÂŽ (OPRX) provides unique physician and consumer platforms and strategie...
OptimizeRxÂŽ (OPRX) provides unique physician a...
Aurinia is a late clinical stage biopharmaceutical company focused on developing a...
Aurinia is a late clinical stage biopharmaceuti...
Join the National Investor Network and get the latest information with your interests in mind.